论文部分内容阅读
探讨IL—2/LAK细胞在介入式局部应用中的抗肿瘤作用,寻求疗效确切、操作可行的晚期肺癌生物治疗的应用途径。我们对60例晚期肺癌随机分为治疗组对照1组和对照2组。治疗组采用经皮颈外静脉穿刺肺分支动脉插管留置、IL—2、LAK细胞及化疗药物联合滴注治疗;对照1组以相同生物制剂及化疗药物外周静脉应用;对照2组采用单纯静脉化疗。三组化疗药物剂量及疗程均相同。结果:三组有效率(CR+PR)分别为:治疗组53.3％,对照1组39.9％,对照2组33.3％。结论:IL—2、LAK细胞与化疗药物联合应用能起到抗肿瘤的协同作用。IL—2、LAK细胞介入式局部应用弥补了其在体内半衰期短的缺陷,使肿瘤靶组织获得大剂量免疫细胞成为可能,从而提高其抗肿瘤作用。
To explore the anti-tumor effects of IL-2/LAK cells in invasive topical applications, and to find out the effective and feasible methods for the application of advanced lung cancer biological therapy. We randomly assigned 60 cases of advanced lung cancer to treatment group 1 and control 2 groups. Patients in the treatment group were treated with percutaneous external jugular vein puncture, pulmonary branch artery intubation, IL-2, LAK cells, and chemotherapeutic drugs infusion; control group 1 was treated with the same biological agent and chemotherapy drug in the peripheral vein; control group 2 was treated with simple intravenous Chemotherapy. The doses and course of treatment of the three groups of chemotherapy drugs were the same. Results: The three groups of effective rate (CR+PR) were: 53.3% in the treatment group, 39.9% in the control group 1, and 33.3% in the control group 2. Conclusion: The combined application of IL-2, LAK cells and chemotherapeutic drugs can play an anti-tumor synergistic effect. The interventional local application of IL-2 and LAK cells makes up for the short-lived half-life in vivo, making it possible to obtain high-dose immune cells in tumor target tissues, thereby increasing its anti-tumor effect.